Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 15, 2012 (Vol. 32, No. 18)

Melina II

URL:melina2.hgc.jp/public
  • Nice results display, easy to use
  • Screen shots in help section too small to read

Just as insurance companies boast that they allow shoppers to compare multiple competitors’ rates simultaneously, Melina II is a one-stop online resource for researchers looking to identify potential DNA binding motifs within their sequences of interest. With Melina II, users can analyze their input sequence with up to four promoter analysis programs simultaneously. The five programs from which to choose are: Consensus, MEME, Gibbs sampler, MDscan, and Weeder. Results are displayed in an easy-to-interpret manner, including an alignment that compares the results from each prediction program. In addition to customizable search parameters, Melina II is also equipped with options to either search for the identified consensus sequences in the genome of human, mouse, B. subtilis, or E. coli, or to compare the identified sequence against known transcription factor binding sites.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »